key: cord-1035155-zekjezhi authors: Chakraborty, Moutoshi; Munshi, Saurab Kishore title: The prospects of employing probiotics in combating COVID-19 date: 2021-10-05 journal: Tzu Chi Med J DOI: 10.4103/tcmj.tcmj_104_21 sha: f528b1c522cac7bd56c9abed4f59cf6c52c6bd61 doc_id: 1035155 cord_uid: zekjezhi Unanticipated pathogenic risk and emerging transmittable diseases can result from interspecies exchanges of viruses among animals and humans. The emergence of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing coronavirus disease-19 (COVID-19) pandemic has recently exemplified this mechanism. Cough, fever, fatigue, headache, sputum production, hemoptysis, dyspnea, diarrhea, and gastrointestinal disorders are the characteristic features of the disease. The most prevalent and serious manifestation of the infection tends to be pneumonia. The new strains of SARS-CoV-2 with more infectivity have been emerging at regular intervals. There is currently no World Health Organization-approved particular drug for COVID-19. Besides, developing novel antivirals would take much time. Thus, repurposing the application of natural products can provide alternatives and can facilitate medication against COVID-19 as well as can slow down the aggressive progression of the disease before the arrival of approved drugs. Probiotics have long been known for their positive effects on the gut microbiome and impact on immune responses. Particularly, their involvement against viral diseases, especially those of the upper and lower respiratory tract, is of current interest for their prospective application against COVID-19. In this review, we comprehensively address the mode of action of probiotics and their possible intervention against coronavirus diseases correlating with their efficacy against viral diseases. In this regard, we explored recently published relevant research and review articles in MEDLINE/PubMed related to COVID-19 and the effects of probiotics on viral infections. D uring the 2 nd week of December 2019, several pneumonia cases of unknown sources registered at a small regional fish and wild animal marketplace in Wuhan, Hubei Province in China [1] . The Chinese Center for Disease Control and Prevention reported this disease as a novel coronavirus infection on January 7, 2020, and on February 11, 2020, the World Health Organization (WHO) declared a new name for the epidemic as 2019-new coronavirus disease (2019-nCoV) which currently referred as coronavirus disease-19 (COVID-19) [2] . In addition, the causative agent of COVID-19 was named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). On March 11, 2020 , when the number of infected countries was 114, with over 118,000 cases and more than 4000 deaths, the WHO announced COVID-19 as a global pandemic [2, 3] . The occurrence of COVID-19 is not the 1 st epidemic or pandemic by a coronavirus. The epidemic of SARS-CoV and Middle East respiratory a B.1.1.7 in UK and B.1.351 in South Africa) with more transmissibility and severity in recent times heightened the risk of COVID-19 by many folds and initiates a second or third wave of infection in many countries [12, 13] . Many countries are trying hard to implement effective prevention and control measures [14] . The design and formulation of successful antiviral agents are largely obstructed as the viruses are obligate intracellular parasites and multiplying inside the host cells [15] . No specific COVID-19 therapeutic is currently available since the production of novel antiviral medications takes a significant amount of time and resources to formulate and validate drugs [14, 16] . A few potential vaccines got approval and have started to be implemented in many countries but their efficiency for long-term protection and potential to combat the emerging variants is in doubt [17, 18] . The application of natural substances such as probiotics may provide solutions in this situation and can facilitate treatment against COVID-19. Probiotics are live microorganisms that offer a health advantage to the host when delivered in adequate amounts [19] . Lactobacillus rhamnosus, Lactobacillus reuteri, and certain strains of Lacticaseibacillus casei, Bifidobacteria spp., Bacillus coagulans, Escherichia coli strain Nissle 1917, Enterococcus faecium SF68, and the yeast Saccharomyces boulardii are the common probiotic microbes [20] . They can strengthen the host immunity by boosting the concentration of useful microbiota, enhancing the functionality of the gastrointestinal barrier, modifying the gut microbiota, competing for epithelial adherence, and immunomodulation, thus reducing gastrointestinal diseases and also respiratory tract infections (RTIs) [21] . Several clinical findings suggest that gastrointestinal signs are prevalent in COVID- 19 and are linked to the severity of the disease [22, 23] . Probiotics are safe and are usually supplied as a part of fermented foods such as yogurt and other dairy food products [24] . They can also be delivered symbiotically with prebiotics that can promote the growth or activity of probiotic microbes [25] . The pathway of how the host species and immune system functionally interact with probiotics is complex and not yet fully explained. This review will focus on the overview of COVID-19 pathogenicity and the difficulties associated with generating and implementing rational remedial options against COVID-19. This is an attempt to justify the probability of employing probiotics as means to reduce the severity of COVID-19 caused by SARS-CoV-2 through analyzing the mode of action of probiotics against viral diseases. Mechanism of action COVID-19 is an infectious viral disease that can spread by inhalation or absorption of viral droplets as a consequence of coughing and sneezing, and touching the contaminated surface [26] . SARS-CoV-2 contains four structural proteins, such as nucleocapsid, spike, membrane, and envelop protein, and other nonstructural proteins [26] . The inhaled virus particles in the nasal cavity bind to the epithelial cell receptor angiotensin-converting enzyme-2 (ACE2) through its spike protein to gain intracellular access and begin to replicate [27] . The virus continues to proliferate and concurrently passes through the airways across the respiratory tract, and clinical signs begin to emerge [28] . The virus is confined to the upper respiratory airways in about 80% of affected individuals who only show mild illness. However, the virus travels down to the lower respiratory tract in about 20% of people and induces severe illness. The viruses enter the lungs' alveoli and infect type II alveolar cells, and multiply there [29, 30] . Viral particles act as a pulmonary toxin after inducing apoptosis of alveolar type II cells, while they further invade type II cells in neighboring alveoli [31] . Wide areas of the lung will subsequently lose most of their type II cells resulting in alveolar damage, called lung fibrosis. Other immune cells (neutrophils, macrophages, T cells, dendritic cells [DCs], etc.) are then activated from the blood, and a robust innate and enhanced immune system is triggered to reverse the damages caused in certain patients. This event may lead to a cytokine storm [32] . Unregulated production of cytokines (interleukin-2 [IL-2], IL-6, IL-17, granulocyte macrophage colony stimulating factor, INF-g, etc.) is known as cytokine storm which aggravates the systemic inflammatory reaction and fibrosis of the lungs that could potentially contribute to acute respiratory distress syndrome (ARDS) [31] . COVID-19's clinical presentations range from asymptomatic types to clinical complications marked by multiorgan and systemic signs of respiratory failure [11] . Cough, fever, and weakness are the most frequent symptoms, alongside patients may also experience headache, hemoptysis, sputum production, dyspnea, diarrhea, and gastrointestinal disturbances [33, 34] . Recent research has shown that lung membranes, kidney cells, and cells in testes' seminiferous ducts have relatively higher ACE2 expression [34] . As a result, COVID-19 can bind directly to some of these ACE2 carrying cells and damage patients' kidneys and testicular tissues [35] . Researchers found several signs and symptoms in the gastrointestinal system during COVID-19, including loss of smell or taste, loss of appetite, vomiting, diarrhea, and other gastrointestinal tract disorders. Compared to persons without gastrointestinal tract complications, the physical condition of persons having gastrointestinal complications during COVID-19 infection is worse. In the gastrointestinal tract, COVID-19 kills the gut bacteria that trigger these manifestations [36, 37] . Individuals with moderate symptoms have been reported to improve after 1 week, while serious cases of progressive respiratory dysfunction leading to alveolar damage by the virus have been reported to result in serious complications, even death [38] . Unfortunately, no drug against COVID-19 has yet officially been approved. The primary health management approach focuses on reducing clinical complications and supporting treatment, including sufficient oxygen and mechanical ventilation when needed [39] . Pressure has been rising to seek a selective drug to combat the virus effectively. The main goal of this effort has been to repurpose existing drugs included with virus-binding molecules, molecules or inhibitors targeting particular enzymes engaged in viral transcription and replication, small molecule inhibitors targeting important proteases or other viral proteins, RNA synthesis, Janus kinases, and inhibit viral S protein interacting with ACE2 [40, 41] . Numbers of anti-CoV agents are available, largely preclinical chemicals that yet to be assessed as anti-COVID-19 drugs. Few of these drugs have already been included in COVID-19 phase III and IV trials, such as favipiravir, remdesivir, oseltamivir, ribavirin, ASC09F, lopinavir, ritonavir, hydroxychloroquine, darunavir, and cobicistat [ Table 1 ]. To date, there is a lack of supportive data on the safety and effectiveness of the drugs currently used for the treatment of other CoV diseases [54, 55] . However, researchers may need long-term research work to generate, manufacture, standardize, evaluate, and trade novel medicines for this emerging virus. Since Elie Metchnikoff first discovered probiotic microorganisms, numerous studies have been conducted on the impacts of probiotics on the immune system of the host [56] . Probiotics are characterized by the WHO and FAO as "living microbes that impart a health gain on a host when delivered in adequate amounts" [56] . The health benefits of Lactobacillus spp. and Bifidobacterium spp. on the host have been proven [20] . With advanced and intensive scientific efforts, novel strains and genera of probiotics are constantly evolving. Probiotics have been shown to shorten the duration of respiratory illnesses and reduce vulnerability to pathogens [57] . Hence, the use of probiotics could plausibly aid in the prevention of respiratory complications in the cases of COVID-19. Although SARS-CoV-2 transmission is assumed to occur primarily through respiratory droplets, the intestine can also take part in COVID-19 pathogenesis [22, 23, [58] [59] [60] . To understand their role against gastrointestinal manifestations of COVID-19, there is a need to evaluate the nutritional and gastrointestinal activity of probiotics [31, 61] . The probiotic mechanisms against viral infections and their potential application against COVID-19 complications are discussed below. Mechanisms that may justify the therapeutic effectiveness of probiotics involve adhesion and coaggregation abilities, competition for nutrient sources and binding sites, the release of antimicrobial compounds, strengthening of intestinal barrier activity through modulation of tight junctions and mucin secretion, and immunomodulation through interaction with microbe-associated molecular pattern (MAMP) receptors [62] [63] [64] [65] [66] . Studies have shown that probiotics may help reduce the occurrence of diarrhea and rotavirus shedding [67, 68] suggesting their interaction with viral entrance and suppression of viral replication in the gut. Probiotics have the potential to suppress purine in foods and drinks. Purines are crucial for the synthesis of viral RNA. Lowering in purine supply can decelerate the replication of viruses and prevent viral infectious diseases [69] [70] [71] . Decreasing purine accessibility may therefore be an essential mechanism of probiotics against viral illnesses. This mechanism may contribute to the reduction of COVID-19 spread through the intestines and thereby might prevent SARS-CoV-2 associated diarrhea. Probiotics may also resist coronavirus replication by reducing endoplasmic reticulum stress-associated autophagy, particularly inositol requiring enzyme-1 mechanisms, over its own anti-IL-17 impact [72] . Evidently, a cytokine storm tends to be the key pathogenic event that triggers viral infection-induced pneumonia [73] . Probiotics take part in plasma pro-inflammatory cytokine (tumor necrosis factor alpha and/or IFN-γ) suppression and anti-inflammatory cytokine (IL-4 and/or IL-10) enhancement, along with decreasing oxidative stress rates and plasma peroxidation [74] , which reduces the incidence, duration, and signs of RTIs [75] . In view of the cytokine storm, which appears to happen in many COVID-19 patients, this immune-modulation probably has some impact [37, 73] . Bacterial secondary pneumonia is a major complication during any pandemic and epidemic by respiratory viral diseases that can increase mortality and morbidity. Bacterial association and colonization, destruction of epithelial barriers, and modification of the respiratory tract's innate immune system are promoted by viral infections [64] . An experiment showed that metabolites such as peptidoglycan from microbiome metabolism enhanced the innate respiratory antiviral immune response and reduced bacterial proliferation in the lung and respiratory inflammatory injury [76] . Vitamins synthesized by the intestinal microbiota may critically involve in the regulation of the immune system [77] . Moreover, probiotic strains were reported to increase the concentration of butyrate (a colonocyte fuel) by raising the integrity of tight junctions [78] . A cascade of the immune response is induced against microorganisms regulated by the interaction of pattern recognition receptors of epithelial cells, DCs, and macrophages with MAMPs [79] . Hence, probiotics, by binding their MAMPs (lipoteichoic acids, peptidoglycan, S-layer proteins, and nucleic acids) with PPRs (toll-like receptors, NOD-like receptors, C-type lectin receptors) expressed in the host intestinal mucosa, can modulate the immune system [79, 80] . Interestingly, differential immunomodulatory capacities of probiotic strains lie on the differences in MAMP profiles [79] . Probiotics can thereby help align inflammatory responses to pathogens with the normal homeostasis of the intestine and their function. The entire immune system could be benefited from the restoration of homeostasis in the gut microbiome by probiotics which consequently favor the gut immune response to act against respiratory infections [79] . This circumstance may also have some impact on COVID-19 infection. In addition to stimulating the gut barrier and metabolic functions, probiotics can colonize and elicit immunomodulatory effects [66] . Lungs have their own microbiota and an intestinal link. A host microbiota and immune interactions may affect the path of respiratory diseases [81] . Imbalance in the microbial communities of the respiratory and gastrointestinal tracts may result in RTIs such as influenza [82, 83] . This dysbiosis may also lead to secondary bacterial infections by altering subsequent immune responses. COVID-19 might have an association with intestinal dysbiosis which can be resolved possibly through the restoration of gut homeostasis by employing probiotic strains [31, 84] . It has also been shown that probiotic bacterial strains control mucin expression, strengthen the mucosal layer and indirectly help the gut's immune system [62] . Also, the intestinal microbiome has a vital impact on systemic immune responses [85, 86] . Probiotic strains can accelerate the number and activity of antigen-presenting cells, NK cells, and T cells, as well as increase the levels of type 1 interferon and specific antibodies (systemic and mucosal) in the lungs [86] [87] [88] . Probiotic strains can also able to change the complex balance between proinflammatory and immunoregulatory cytokines, which allow for viral clearance as well as reduce immune-response damage to the lungs. This could be of particular concern if the COVID-19 complication of ARDS is to be avoided. Probiotics can not only prevent GTI and antibiotic-related diarrhea infections may also prevent infections elsewhere, such as sepsis and RTI infections [89] [90] [91] [92] [93] [94] [95] . A randomized, double-blind, placebo-controlled clinical trial on 70 children getting yogurt with probiotics L. rhamnosus GG, Bifidobacterium lactis, and L. acidophilus reported a boosting of gastrointestinal well-being and resolved digestive symptoms and a decline in gastrointestinal disorders [96] . Some reports evident that antibiotic-associated diarrhea has been prevented by Lactobacillus and Bifidobacterium [97] [98] [99] [100] . Viruses are responsible for over 90% of upper RTIs [57] . Several studies have reported the positive effect of probiotics on the prevention of upper RTIs. In a meta-analysis of 12 randomized control trials (RCTs), 3,720 adults and children who were provided with probiotics showed a 2-fold lower risk of developing upper RTI and the severity of the disease has been reduced small-scale but substantial [57] . A study with 479 adults reported Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, and Bifidobacterium bifidum MF 20/5 along with vitamins and minerals to reduce the length of common cold symptoms including the duration with fever [87] . Several studies documented the impact of probiotics on the prevention of viral upper RTIs infections as well. An RCT, including 94 preterm infants, showed that the incidence of clinically defined virus-associated RTI was reduced by 2-3 folds by the prebiotic mixture of Galacto-oligosaccharides and polydextrose (1:1), or probiotic L. rhamnosus GG, given between 3 and 60 days after their birth [101] . It was evident by a report that live L. rhamnosis GG may be more efficient than the inactivated form of the same strain to minimize rhinovirus infection [102] . An open-label study on 1783 school children reported a decreased incidence of RTI influenza following ingestion of Lactobacillus brevis [103] . Reduction in the sepsis and lower RTI were elucidated in an RCT including >4000 infants in India treated with a strain of Lactobacillus plantarum in combination with prebiotics [104] . The pieces of evidence suggest that this pandemic is affecting adults more than children. An RCT found promising results against viral diseases in 27 elderly individuals receiving Bifidobacterium longum [88] . Furthermore, lactic acid bacteria, which are prominent sources of probiotics, are found to be a part of the upper respiratory tract microbiota in healthy people and some strains have the reputation of preventing recurrent otitis media [105] . Probiotics have been shown to have some impacts on common colds and upper respiratory infections in adults [106] . Several studies reported that the innate inflammatory response against the rhinovirus has an association with their pathogenesis for the common cold [107] . Hence, several attempts have been made to modulate the immune response optimally for combating viral infections by employing probiotics [108] . In this respect, an investigation was carried out to determine the impact of Bifidobacterium animalis ssp. Lactis Bl-04 on human rhinovirus in healthy adults [107] . They reported the reduction in CXCL8 response in the nasal lavage which resulted in a decline in the rhinovirus replication. They claimed a modest modulation of innate immune host responses as a decrease in virus shedding in the nasal secretions was found. Another study by Wang et al. [109] assessed the impact of administering L. rhamnosus GG in elderly patients of 65 and more ages admitted in the nursing home. According to their findings, the elderly individuals were found to become less vulnerable to influenza and other respiratory viral infections when administered with probiotics compared to placebo receiving individuals. A study on the other hand found no effect on the rate of influenza infection following ingestion of yogurt fermented with probiotic Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 though an acceleration in IFN-α level in the probiotic treated group was observed by the immunological analysis [110] . A meta-analysis with nearly 2,000 patients found that probiotics could minimize ventilator-associated pneumonia and critical disease incidences [111] . Hu et al. [112] found H7N9 influenza A virus infection to be responsible for lowering the intestinal microbial diversity as well as microbiome in patients. They reported a gradual increase in the microbial diversity and innate immunity by continuous administration of probiotics after withdrawal of antibiotic treatment. Such clinical shreds of evidence let us consider highlighting the use of probiotics to slow down the progression of the coronavirus pandemic. Some current investigations also supported this assumption. Liu et al. [113] , for example, demonstrated that their modified Lactobacillus plantarum acts in the intestinal porcine epithelial cell line as a potent anti-coronaviral agent. Verma et al. [114] evident the production of ACE-2 (well known as a receptor for SARS-CoV-2 binding) in Lactobacillus paracasei. If this ACE-2 can successfully bind the spike protein of SARS-CoV-2, their entry into the host cell will be prevented and thereby, the risk of infections will be lowered [115] . Furthermore, a clinical survey recorded gut microbiome imbalances including a decrease in probiotic levels such as Lactobacillus and Bifidobacterium among some patients with COVID-19, which may lead to secondary infection in response to bacterial translocation [31] . The evidence suggests the role of oral probiotics against the intestinal and systemic effects of COVID-19 [116] . Xu et al. [117] in their study found most of the COVID-19 patients who received probiotics encountered relatively mild symptoms. Baud et al. [118] found a profound correlation between the application of different probiotics such as Lactobacillus casei, Lactobacillus plantarum, L. rhamnosus, Lactobacillus gasseri, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium breve, Leuconostoc mesenteroides, and Pediococcus pentosaceus and the lowering of complications due to COVID-19 in a large human study population. Wu et al. [119] observed a remarkable reduction in COVID-19 symptoms along with the lowering of inflammation and restoration of gut microbiota after taking a large dose of probiotics. Current research in Belgium evident the efficacy of different lactobacilli in reducing the viral activity in the nasopharynx and oropharynx through mediating enhancement in the epithelial barrier and anti-inflammatory effects alongside minimizing the risk of secondary bacterial infections in COVID-19 [120] . d'Ettorre et al. [121] examined the potential of oral bacteriotherapy formulated with Streptococcus thermophiles DSM 32345, L. acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus Plantarum DSM 32244, Lactobacillus brevis DSM 27961, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247 against the progression of COVID-19 complications. Patients who received bacteriotherapy showed a higher survival rate and were with a lower risk of developing respiratory collapse along with notable improvement in other manifestations of COVID-19 in 24-48 h of administration possibly through promoting host immunity. Although several randomized controlled studies have shown that probiotic administration in COVID-19 patients can thwart ventilator-associated pneumonia, the impact on mortality reduction remains unknown [122, 123] . However, the study of probiotic therapies could be appropriate during a pandemic. A list of different probiotics which may have a prospect against COVID-19 is given in Table 2 along with their sources, effects, and possible mechanisms. By modulating host immune responses, upholding gut homeostasis, and releasing interferon, the probiotics have the potential to control the cytokine storm caused by SARS-CoV-2 [30, 31] . The promising effect has been shown by Lactobacilli and Bifidobacteria, against SARS-CoV-2 induced gut dysbiosis. The approach involving modulation of intestinal microbiota can be considered as one of the therapeutic options against COVID-19 and its comorbidities. However, in combating COVID-19, the prospect of using probiotics remains uncertain and a lot remains to be learned. In particular, specific beneficial strains have to be distinguished since each strain exerts a certain effect. Governments are funding several drug development and testing research. They also need to finance probiotic studies. Owing to excel the dissemination of probiotic strains and native beneficial microbes, the use of established prebiotics (e.g. fructans or galactans) should also be recommended. As soon the probiotic research enters the next step, the mode of action of each probiotic and its effective clinical use are required to be determined. If the forthcoming clinical trials rely on characterizing the effect of introducing probiotics on the baseline individual microflora and their genetic pattern of responses, the potency of probiotic application in human disease prevention and treatment can thereby be revealed. This adds to future demand for custom medicinal products. Furthermore, current translational and Contd... Contd... Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle Available from: https:// www.who.int/director-general/speeches/detail/who-director-general-sremarks-at-the-media-briefing-on COVID-19: A fast evolving pandemic Coronaviruses-drug discovery and therapeutic options Epidemiology, genetic recombination, and pathogenesis of coronaviruses Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies The SARS-CoV-2 outbreak from a one health perspective A pneumonia outbreak associated with a new coronavirus of probable bat origin Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China SARS-CoV-2 variants and ending the COVID-19 pandemic SARS-CoV-2 variants of concern are emerging in India How will country-based mitigation measures influence the course of the COVID-19 epidemic? Antiviral chemotherapy in veterinary medicine: Current applications and perspectives The need for antiviral drugs for pandemic coronaviruses from a global health perspective Looking beyond COVID-19 vaccine phase 3 trials World Health Organization. The Effects of Virus Variants on COVID-19 Vaccines Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model Probiotics in the intensive care unit Epidemiological, clinical and virological characteristics of 74 cases of coronavirusinfected disease 2019 (COVID-19) with gastrointestinal symptoms Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection Probiotics dietary supplementation for modulating endocrine and fertility microbiota dysbiosis Probiotics: What You Need to Know. US Department of Health and Human Services Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: Role of ciliated cells in viral spread in the conducting airways of the lungs Pathology and pathogenesis of Severe Acute Respiratory Syndrome Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus Pathological findings of COVID-19 associated with acute respiratory distress syndrome Pathogenesis of COVID-19 from a cell biology perspective Novel Wuhan (2019-NCoV) coronavirus Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention ACE2 Expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection Intestinal Flora as a potential strategy to fight SARS-CoV-2 infection Probiotics in the prophylaxis of COVID-19: Something is better than nothing Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Evaluation and Treatment Coronavirus (COVID-19) Anti-SARS coronavirus agents: A patent review (2008-present) Drug treatment options for the 2019-new coronavirus (2019-nCoV) Antivirals targeting the polymerase complex of influenza viruses Type 1 interferons as a potential treatment against COVID-19 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Hydroxychloroquine in the management of critically ill patients with COVID-19: The need for an evidence base Old weapon for new enemy: Drug repurposing for treatment of newly emerging viral diseases Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs Probioticsidentification and ways of action Probiotics for preventing acute upper respiratory tract infections COVID-19 and the gastrointestinal tract: More than meets the eye Viral load of SARSCoV-2 in clinical samples SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases Preventing respiratory tract infections by synbiotic interventions: A systematic review and metaanalysis of randomized controlled trials The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells Beneficial effects of probiotic consumption on the immune system Probiotics interaction with foodborne pathogens: A potential alternative to antibiotics and future challenges Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus Modulation of rotavirus severe gastroenteritis by the combination of probiotics and prebiotics Evaluation of purine utilization by Lactobacillus gasseri strains with potential to decrease the absorption of food-derived purines in the human intestine Reducing effect of Lactobacillus gasseri PA-3 on the absorption of foodderived purines Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: A randomised, double-blind, placebocontrolled study Bifidobacteria and mucosal-associated invariant T (MAIT) cells: A new approach to colorectal cancer prevention? COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate Peptidoglycan from immunobiotic Lactobacillus rhamnosus improves resistance of infant mice to respiratory syncytial viral infection and secondary pneumococcal pneumonia Interactions between intestinal microflora/ probiotics and the immune system Regulation of inflammation by short chain fatty acids Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health The gut-lung axis in health and respiratory diseases: A place for inter-organ and inter-kingdom crosstalks Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SAR S-CoV-2 Commensal bacteria calibrate the activation threshold of innate antiviral immunity Respiratory antiviral immunity and immunobiotics: Beneficial effects on inflammationcoagulation interaction during influenza virus infection Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly A new chance of preventing winter diseases by the administration of synbiotic formulations Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial The clinical and economic impact of probiotics consumption on respiratory tract infections: Projections for Canada Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Probiotics for the prevention of pediatric antibiotic-associated diarrhea Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children-a 2019 update Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and meta-analysis Yogurt for treating antibioticassociated diarrhea: Systematic review and meta-analysis Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibioticassociated diarrhoea in children and adults Probiotics reduce the risk of antibioticassociated diarrhea in adults (18-64 years) but not the elderly (>65 years): A meta-analysis Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial The use of the probiotic Lactobacillus rhamnosus GG and viral findings in the nasopharynx of children attending day care Effects of probiotic Lactobacillus brevis KB 290 on incidence of influenza infection among school children: An open-label pilot study A randomized synbiotic trial to prevent sepsis among infants in rural India Specific probiotics in reducing the risk of acute infections in infancy -a randomised, double-blind, placebocontrolled study Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection-a randomised controlled trial Control of antiviral immunity by pattern recognition and the microbiome Probiotics to prevent respiratory infections in nursing homes: A pilot randomized controlled trial The effects of OLL1073R-1 yogurt intake on influenza incidence and immunological markers among women healthcare workers: A randomized controlled trial Probiotics for preventing ventilator-associated pneumonia The effect of probiotic treatment on patients infected with the H7N9 influenza virus Surfacedisplayed porcine IFN-λ3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells Expression of human ACE2 in Lactobacillus and beneficial effects in diabetic retinopathy in mice Probiotics in the prophylaxis of COVID-19: Something is better than nothing Oral probiotics in coronavirus disease 2019: Connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic The volatile and heterogenous gut microbiota shifts of COVID-19 patients over the course of a probiotics-assisted therapy International Scientific Association of Probiotics and Prebiotics Board of Directors. How some Probiotic Scientists are Working to Address COVID-19 Challenges in the management of SARS-CoV2 infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19 Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19 Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARSCoV-2; 2020 Human rhinoviruses The efficacy of probiotics in the treat-ment of irritable bowel syndrome: A systematic review A meta-analysis of probiotic efficacy for gastrointestinal diseases Daily JW 3 rd . Health benefits of kimchi (Korean fermented vegetables) as a probiotic food Lactobacillus plantarum 299 v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics Synbiotics modulate gut microbiota and reduce enteritis and ventilatorassociated pneumonia in patients with sepsis: A randomized controlled trial Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: Randomised, double blind, placebo-controlled pilot trial Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 ingestion induces a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults: A randomized, double-blind, placebo-controlled, crossover study Probiotic and symbiotic therapy in critical illness: A systematic review and metaanalysis Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: A controlled trial in liver transplant recipients Oral probiotic and prevention of Pseudomonas aeruginosa infections: A randomized, double-blind, placebo-controlled pilot study in intensive care unit patients Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea Probiotics for treating acute infectious diarrheae Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding Randomised, doubleblind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections Human rhinovirus in experimental infection after peroral Lactobacillus rhamnosus GG consumption, a pilot study Oral intake of Lactobacillus rhamnosus M21 enhances the survival rate of mice lethally infected with influenza virus Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: A randomised, double-blind, parallel, controlled study Effect of long term consumption of probiotic milk on infections in children attending day care centres: Double blind, randomised trial A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: Early results of a randomized controlled trial The authors would like to thank all the researchers whose articles are cited in this manuscript. Nil. There are no conflicts of interest.